Loading...
•
Mar 31, 2022
DBV Technologies Q1 2022 Earnings Report
DBV Technologies reported financial results for Q1 2022 and provided business updates on Viaskin Peanut's regulatory status.
Key Takeaways
DBV Technologies reported a net loss of $16.7 million for the first quarter of 2022, with cash and cash equivalents totaling $74.1 million. The FDA granted a Type C meeting to align on the new Viaskin Peanut Phase 3 study protocol. The company expects its current cash and cash equivalents to support operations into Q1 2023.
FDA granted DBV Technologies a Type C meeting to align on the new Viaskin Peanut Phase 3 study protocol.
The study protocol was submitted to the FDA as part of the Type C briefing materials.
Cash and cash equivalents were $74.1 million as of March 31, 2022.
DBV expects top-line results of the EPITOPE trial by the end of Q2 2022.
DBV Technologies
DBV Technologies
Forward Guidance
DBV expects that its current cash balance will sufficiently support Company operations while alignment with the FDA on the VITESSE protocol is achieved and anticipates its current cash and cash equivalents will support its operations into the first quarter of 2023.